Search Results

There are 6992 results for: content related to: Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer

  1. You have free access to this content
    Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck

    Cancer

    Volume 120, Issue 24, December 15, 2014, Pages: 3940–3951, Nabil F. Saba, Selwyn J. Hurwitz, Kelly Magliocca, Sungjin Kim, Taofeek K. Owonikoko, Donald Harvey, Suresh S. Ramalingam, Zhengjia Chen, Jackie Rogerio, Jennifer Mendel, Scott A. Kono, Colleen Lewis, Amy Y. Chen, Kristin Higgins, Mark El-Deiry, Trad Wadsworth, Jonathan J. Beitler, Dong M. Shin, Shi-Yong Sun and Fadlo R. Khuri

    Version of Record online : 7 AUG 2014, DOI: 10.1002/cncr.28965

  2. You have free access to this content
    Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study

    Cancer

    Volume 120, Issue 16, August 15, 2014, Pages: 2457–2463, Emilio Bajetta, Laura Catena, Nicola Fazio, Sara Pusceddu, Pamela Biondani, Giusi Blanco, Sergio Ricci, Michele Aieta, Francesca Pucci, Monica Valente, Nadia Bianco, Chiara Maria Mauri and Francesca Spada

    Version of Record online : 18 APR 2014, DOI: 10.1002/cncr.28726

  3. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer

    Cancer

    Volume 122, Issue 12, June 15, 2016, Pages: 1897–1904, Helen Chow, Paramita M. Ghosh, Ralph deVere White, Christopher P. Evans, Marc A. Dall'Era, Stanley A. Yap, Yueju Li, Laurel A. Beckett, Primo N. Lara Jr and Chong-Xian Pan

    Version of Record online : 28 MAR 2016, DOI: 10.1002/cncr.29927

  4. You have free access to this content
    Mechanisms of Everolimus-Induced Glomerulosclerosis After Glomerular Injury in the Rat

    American Journal of Transplantation

    Volume 5, Issue 12, December 2005, Pages: 2849–2861, C. Daniel, L. Renders, K. Amann, E. Schulze-Lohoff, I.A. Hauser and C. Hugo

    Version of Record online : 18 NOV 2005, DOI: 10.1111/j.1600-6143.2005.01120.x

  5. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications

    Cancer

    Volume 121, Issue 21, November 1, 2015, Pages: 3853–3861, Dana E. Rathkopf, Steven M. Larson, Aseem Anand, Michael J. Morris, Susan F. Slovin, David R. Shaffer, Glenn Heller, Brett Carver, Neal Rosen and Howard I. Scher

    Version of Record online : 15 JUL 2015, DOI: 10.1002/cncr.29578

  6. You have free access to this content
    A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor

    Cancer

    Volume 119, Issue 17, 1 September 2013, Pages: 3212–3218, Jennifer A. Chan, Lawrence Blaszkowsky, Keith Stuart, Andrew X. Zhu, Jill Allen, Raymond Wadlow, David P. Ryan, Jeffrey Meyerhardt, Marielle Gonzalez, Eileen Regan, Hui Zheng and Matthew H. Kulke

    Version of Record online : 3 JUN 2013, DOI: 10.1002/cncr.28142

  7. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain

    Liver Transplantation

    Volume 21, Issue 8, August 2015, Pages: 1056–1065, Itxarone Bilbao, Magdalena Salcedo, Miguel Angel Gómez, Carlos Jimenez, Javier Castroagudín, Joan Fabregat, Carolina Almohalla, Ignacio Herrero, Valentín Cuervas-Mons, Alejandra Otero, Angel Rubín, Manuel Miras, Juan Rodrigo, Trinidad Serrano, Gonzalo Crespo, Manuel De la Mata, Javier Bustamante, M. Luisa Gonzalez-Dieguez, Antonia Moreno, Isidoro Narvaez, Magda Guilera and for the EVEROLIVER study group

    Version of Record online : 24 JUL 2015, DOI: 10.1002/lt.24172

  8. Blood Concentrations of Everolimus Are Markedly Increased by Ketoconazole

    The Journal of Clinical Pharmacology

    Volume 45, Issue 5, May 2005, Pages: 514–528, Dr J. M. Kovarik, Dr D. Beyer, Dr M. N. Bizot, Dr Q. Jiang, Dr M. Shenouda and Dr R. L. Schmouder

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270005275368

  9. You have free access to this content
    Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients

    American Journal of Transplantation

    Volume 10, Issue 6, June 2010, Pages: 1401–1413, H. Tedesco Silva Jr., D. Cibrik, T. Johnston, E. Lackova, K. Mange, C. Panis, R. Walker, Z. Wang, G. Zibari and Y. S. Kim

    Version of Record online : 28 APR 2010, DOI: 10.1111/j.1600-6143.2010.03129.x

  10. Influence of Everolimus on Steady-State Pharmacokinetics of Cyclosporine in Maintenance Renal Transplant Patients

    The Journal of Clinical Pharmacology

    Volume 45, Issue 7, July 2005, Pages: 781–791, Dr Klemens Budde, Dr Gustav Lehne, Dr Michael Winkler, Dr Lutz Renders, Dr Arno Lison, Dr Lutz Fritsche, Dr Jean-Paul Soulillou, Dr Per Fauchald, Dr Hans-Hellmut Neumayer, Dr Jaques Dantal and Behalf of the RADW 102 Renal Transplant Study Group

    Version of Record online : 25 MAR 2013, DOI: 10.1177/0091270005277196

  11. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine

    Clinical Pharmacology & Therapeutics

    Volume 69, Issue 1, January 2001, Pages: 48–56, John M. Kovarik, Barry D. Kahan, Bruce Kaplan, Marc Lorber, Michael Winkler, Marisel Rouilly, Christophe Gerbeau, Natalie Cambon, Robert Boger, Christiane Rordorf and on behalf of the Everolimus Phase 2 Study Group

    Version of Record online : 5 JAN 2001, DOI: 10.1067/mcp.2001.112969

  12. You have full text access to this OnlineOpen article
    Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis

    Cancer Medicine

    Volume 2, Issue 6, December 2013, Pages: 862–871, Kenya Yamanaka, Marius Petrulionis, Shibo Lin, Chao Gao, Uwe Galli, Susanne Richter, Susanne Winkler, Philipp Houben, Daniel Schultze, Etsuro Hatano and Peter Schemmer

    Version of Record online : 22 OCT 2013, DOI: 10.1002/cam4.150

  13. You have free access to this content
    Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation

    Transplant International

    Volume 28, Issue 1, January 2015, Pages: 42–51, Lars Mjörnstedt, Søren Schwartz Sørensen, Bengt von zur Mühlen, Bente Jespersen, Jesper M. Hansen, Claus Bistrup, Helene Andersson, Bengt Gustafsson, Dag Solbu and Hallvard Holdaas

    Version of Record online : 30 SEP 2014, DOI: 10.1111/tri.12437

  14. Everolimus: A Proliferation Signal Inhibitor with Clinical Applications in Organ Transplantation, Oncology, and Cardiology

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 30, Issue 10, October 2010, Pages: 1044–1056, Steven Gabardi and Steven A. Baroletti

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.30.10.1044

  15. You have free access to this content
    Therapeutic strategies for neuroendocrine liver metastases

    Cancer

    Volume 121, Issue 8, April 15, 2015, Pages: 1172–1186, Andrea Frilling and Ashley K. Clift

    Version of Record online : 1 OCT 2014, DOI: 10.1002/cncr.28760

  16. You have free access to this content
    Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial

    American Journal of Transplantation

    Volume 13, Issue 5, May 2013, Pages: 1203–1216, H. J. Eisen, J. Kobashigawa, R. C. Starling, D. F. Pauly, A. Kfoury, H. Ross, S.-S. Wang, B. Cantin, A. Van Bakel, G. Ewald, S. Hirt, H. Lehmkuhl, A. Keogh, M. Rinaldi, L. Potena, A. Zuckermann, G. Dong, C. Cornu-Artis and P. Lopez

    Version of Record online : 22 FEB 2013, DOI: 10.1111/ajt.12181

  17. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial

    American Journal of Transplantation

    Volume 15, Issue 7, July 2015, Pages: 1967–1975, S. Arora, A. K. Andreassen, B. Andersson, F. Gustafsson, H. Eiskjær, H. E. Bøtker, G. Rådegran, E. Gude, D. Ioanes, D. Solbu, V. Sigurdardottir, G. Dellgren, I. Erikstad, O. G. Solberg, T. Ueland, P. Aukrust, L. Gullestad and on behalf of the SCHEDULE (SCandinavian HEart transplant everolimus De novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators

    Version of Record online : 17 MAR 2015, DOI: 10.1111/ajt.13214

  18. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

    Annals of the New York Academy of Sciences

    Volume 1291, Issue 1, July 2013, Pages: 14–32, David Lebwohl, Özlem Anak, Tarek Sahmoud, Judith Klimovsky, Ingrid Elmroth, Tomas Haas, Joseph Posluszny, Stephen Saletan and William Berg

    Version of Record online : 9 MAY 2013, DOI: 10.1111/nyas.12122

  19. You have free access to this content
    Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation

    American Journal of Transplantation

    Volume 12, Issue 10, October 2012, Pages: 2744–2753, L. Mjörnstedt, S. S. Sørensen, B. von zur Mühlen, B. Jespersen, J. M. Hansen, C. Bistrup, H. Andersson, B. Gustafsson, L.H. Undset, H. Fagertun, D. Solbu and H. Holdaas

    Version of Record online : 19 JUL 2012, DOI: 10.1111/j.1600-6143.2012.04162.x

  20. You have free access to this content
    Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study

    American Journal of Transplantation

    Volume 12, Issue 6, June 2012, Pages: 1528–1540, K. Budde, F. Lehner, C. Sommerer, W. Arns, P. Reinke, U. Eisenberger, R. P. Wüthrich, S. Scheidl, C. May, E.-M. Paulus, A. Mühlfeld, H. H. Wolters, K. Pressmar, R. Stahl, O. Witzke and On behalf of the ZEUS Study Investigators

    Version of Record online : 5 MAR 2012, DOI: 10.1111/j.1600-6143.2012.03994.x

    Corrected by:

    Erratum

    Vol. 12, Issue 11, 3165, Version of Record online: 27 OCT 2012